Can you spot the trends? We break down the live data on planned and ongoing #raredisease CNS research: https://hubs.ly/Q02G9zNg0 #clinicaltrials #clinicalresearch #drugdevelopment
Precision For Medicine’s Post
More Relevant Posts
-
Compass Pathways CEO Kabir Nath discusses clinical development program of COMP360 psilocybin for Treatment Resistant Depression, development of novel care models and approach to commercialization, on central stage of CNS Summit . Great insights from Amit Etkin about need for precision medicine approach for patient selection in CNS clinical trials and beyond. #mentalhealth #psilocybin #psychedelicresearch #precisionmedicine #valuebasedhealthcare
To view or add a comment, sign in
-
-
Anemia is associated with poor cognitive and motor development in children. Medonic M32 hematology analyzer facilitates anemia investigations in children by allowing for CBC testing directly from a fingerstick blood sample. Read the full article here; https://lnkd.in/dg6vKT2Y #medonic #bloodtesting #capillary #CBC
To view or add a comment, sign in
-
-
After Phase 3 #LASER301 showed that #lazertinib ⬆️PFS compared w #gefitinib, Cicin et al. researched the efficacy of both treatments in pts w baseline CNS mets. They found that lazertinib significantly ⬆️ iPFS compared w gefitinib (HR 0.42) https://bit.ly/3ROOAAV #ESMO23 #LCSM
To view or add a comment, sign in
-
-
For patients with baseline CNS metastases in the #LASER301 study, #lazertinib significantly improved iPFS versus gefitinib, with more durable responses and a tolerable safety profile, suggesting that lazertinib has the potential to improve CNS outcomes in patients with EGFR-mutated NSCLC. https://lnkd.in/gf7qJmsE
After Phase 3 #LASER301 showed that #lazertinib ⬆️PFS compared w #gefitinib, Cicin et al. researched the efficacy of both treatments in pts w baseline CNS mets. They found that lazertinib significantly ⬆️ iPFS compared w gefitinib (HR 0.42) https://bit.ly/3ROOAAV #ESMO23 #LCSM
To view or add a comment, sign in
-
-
Your Free September CE Has Arrived! AANP members can complete "Caring for Patients With Sepsis and Septic Shock" before Sept. 30 to earn 1.0 CH of CE credit, 0.5 CH of which may be applied toward pharmacology. Presented by AANP Acute Care Community Co-chairs Drs. L. Douglas Smith and Paula McCauley, this activity will outline sepsis and septic shock symptoms and help you implement appropriate treatments and strategies to prevent end-organ damage. Learn more: https://bit.ly/3L1SUbt.
To view or add a comment, sign in
-
-
In a randomized trial comparing direct oral anticoagulants (DOACS) with subcutaneous low molecular weight heparin (LMWH) in over 670 patients with cancer-related venous thromboembolism (VTE), rates of recurrent VTE at six months were not significantly different between groups. Despite limitations (e.g., poor adherence rates with LMWH), these and previous data support the administration of either DOACs or LMWH as first-line agents in patients with cancer-associated VTE. Check out What’s New in #CriticalCare: https://ow.ly/YFjH50PCGIj #ClinicalUpdates #meded
To view or add a comment, sign in
-
-
Posthoc analysis of 2 phase III RCTs of ABA x 2 yrs in 409 poly JIA pts; ABA monoRx vs ABA + MTX Rx pts were compared and there were NO between group differences in efficacy (JIA-ACR & JADAS27-CRP), bio-naive vs bio-experience responses, safety & PK studies
To view or add a comment, sign in
-
Today is International Epilepsy Day. Epilepsy is treatable for most people, but it remains misunderstood. Today, we add our voice to help build awareness, particularly regarding the need for new and better treatments. Our own drug candidate, ADX71149, is a selective metabotropic #glutamate type 2 (mGlu2) receptor positive #allostericmodulator (PAM), is currently in Phase 2 clinical development to see if the time between seizures can be prolonged by adding this drug to existing medication. #EpilepsyDay #epilepsy
To view or add a comment, sign in
-
-
Posthoc analysis of 2 phase III RCTs of ABA x 2 yrs in 409 poly JIA pts; ABA monoRx vs ABA + MTX Rx pts were compared and there were NO between group differences in efficacy (JIA-ACR & JADAS27-CRP), bio-naive vs bio-experience responses, safety & PK studies
Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
jrheum.org
To view or add a comment, sign in
-
💫 Following this week’s positive top-line data announcement on BEN-8744, our potential first-in-class treatment for patients with moderate to severe ulcerative colitis, we’ve seen some great media coverage: 📣 Our Chief Scientific Officer Anne Phelan spoke to Stephen Gunnion from Proactive to outline the results, explain how our platform was utilised in target discovery, and confirm what to expect next. https://lnkd.in/etA3qa7u 📣 Thanks also to Caroline Richards who interviewed Anne for BioWorld, where she explained: “PDE10 inhibitors have been studied before for CNS indications; however, they have had substantial neurological side effects thought to be attributable to PDE10 inhibition in the brain that limited their further clinical development.” Importantly, in our phase 1a study, there was no evidence of CNS-associated adverse events. The full article is available here: https://lnkd.in/e6uTQTZQ
Benevolentai’s BEN-8744 shows promise in ulcerative colitis
bioworld.com
To view or add a comment, sign in
Robert Bauer